Notably, Hsp90 inhibitors exhibit selectively higher antitumor effects against ErbB2-overexpressing breast cancer cells and these effects are synergistic with ErbB2-targeted therapeutics Trastuzumab or Lapatinib [31]. This evidence concerns the gene ERBB2 and breast carcinoma.